Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

749.92 -3.49 (-0.46%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
Shares of Eli Lilly hit resistance at the $955 level. Now they are heading lower. These moves are due to investor psychology. 
Via Benzinga
Comparative Study: Eli Lilly And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
The weight loss drug market may soon be worth $100 billion. 
Via The Motley Fool
Shorting The Fatties
Eli Lilly (LLY) has traditionally scared me. It is sporting a P/E in the triple digits, which is normally what you would associate with a new biotech company at the cusp of curing cancer, not an... 
Via Talk Markets
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected. 
Via Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges. 
Via Benzinga
Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points
Via Benzinga
Gilding The Lilly
Via Talk Markets
Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term Trials
Eli Lilly's Weekly Insulin Efsitora Meets Phase 3 Goals, Offering Improved Blood Sugar Control in Type 2 Diabetes. 
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Lilly just lowered the price of Zepbound. 
Via The Motley Fool
Why Walgreens Boots Alliance Fell Another 22% in August
The retail pharmacy giant faces ever-mounting headwinds. 
Via The Motley Fool
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
The companies are well-known for their obesity treatments and could reach a $1 trillion market cap before carmaker Tesla. 
Via Investor's Business Daily
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs a biotech company focused on therapies for metabolic diseases, has filed for a $100 million IPO. Founded in 2015, the company plans to list on Nasdaq under the symbol BIOA. Their lead drug,... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Top Medical Stocks To Hedge Against The September Effect
While the Fed will likely cut interest rates in the coming weeks, September has historically been the most challenging month for stocks. Here are three top medical stocks to hedge against the September... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Eli Lilly Trades Near All-Time High: Check Out The IBD 50, Big Cap 20, Other Top Stock Lists
Lilly, which traces it roots in the industry back 150 years to its founding by chemist Eli Lilly, boasts a best-possible 99 Composite Rating. 
Via Investor's Business Daily
3 Big Winners From The Q2 Earnings Season: LLY, LMT, META
The 2024 Q2 earnings season is slowly grinding to a halt, with the majority of S&P 500 companies already delivering quarterly results. All three listed here posted robust results with shares of each... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Will September Bring A Rebound In Google Stock Amid New Antitrust Trial?
Google stock could face a headline risk from a new antitrust trial starting in September involving advertising technology. 
Via Investor's Business Daily
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound. 
Via Benzinga
Exposures Product Safety
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
These disruptive stocks could reap generous rewards for long-term investors. 
Via The Motley Fool
Market Thoughts This Labor Day Weekend
For this long weekend, I am offering you food for thought. In the overall macro theme, I am sticking to this for time being: Stagflation - The Fed can’t fix it with a huge reduction in rates, that will... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points
While the Nasdaq lagged last week, the S&P 500 entered a power trend Friday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 No-Brainer Stocks to Buy in September
There's at least one key common denominator here: tremendous growth prospects. 
Via The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
This competitive showdown just saw one of the players hit a couple of bumps. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $1,000
Business is booming for these stocks. 
Via The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
A Philadelphia judge's early ruling in the Ozempic and Wegovy litigation may shape the outcome of the lawsuits against Novo Nordisk and Eli Lilly, focusing on the diagnosis of gastroparesis and the... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Novo Nordisk's semaglutide reduced the risk of cardiovascular events in heart failure patients by 31% in recent trials published by The Lancet. While not approved for heart failure outcomes in the US,... 
Via Benzinga
Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind
Eli Lilly may not be an expensive stock when you consider its long-run growth prospects. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.